Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a group of drugs that have attracted a lot of interest in recent years as potential blockbuster therapeutics initially aimed at the treatment of T2DM, but are increasingly being noticed in terms of the multiple levels they can positively influence [7,8]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.